The present invention is directed to stable chemical compositions and dosage forms that comprise nebivolol and valsartan and which achieve therapeutically effective plasma levels of both actives in hypertensive patients following administration, as well as to methods of lowering blood pressure and treating hypertension using such compositions and dosage forms.

The present invention is directed to stable chemical compositions and dosage forms that comprise nebivolol and valsartan and which achieve therapeutically effective plasma levels of both actives in hypertensive patients following administration as well as to methods of lowering blood pressure and treating hypertension using such compositions and dosage forms.

The present invention is directed to stable chemical compositions and dosage forms that comprise nebivolol and valsartan and which achieve therapeutically effective plasma levels of both actives in hypertensive patients following administration as well as to methods of lowering blood pressure and treating hypertension using such compositions and dosage forms.

The present invention provides an improved process for the synthesis of nebivolol or its pharmaceutically acceptable salts more particularly hydrochloride salt of formula (I). The present invention further provides a new Form T1 of nebivolol and its pharmaceutically acceptable salts. The present invention also provides pharmaceutical compositions and process for the preparation of a solid oral dosage form of nebivolol hydrochloride of formula (I) without the use of wetting agent and optionally u...

The present invention relates to a process for the preparation of Nebivolol and more particularly to an improved method of synthesizing 6-fluoro chroman epoxides of formula (I) key intermediates in preparing nebivolol.

The present invention relates to modified nebivolol formate useful in the preparation of highly pure nebivolol.